Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shock waves may loosen stiff ankles after stroke

NCT ID NCT07695038

Symptom relief Sponsor: Pamukkale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial investigates whether adding radial shock wave therapy to standard botulinum toxin injections can further reduce ankle muscle stiffness and improve walking in people who have had a stroke. Participants receive either shock wave therapy plus physical therapy or physical therapy alone after their botulinum toxin injection. The study measures changes in muscle tightness, ankle movement, and walking ability over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radial extracorporeal shock wave therapy (rESWT)
What this could lead to
If effective, adding shock wave therapy to standard botulinum toxin injections could offer a non-drug way to further reduce muscle stiffness and improve walking in stroke survivors.
What could go wrong
This is a small, early-stage trial with only 32 participants, so results may not apply to everyone. The shock wave therapy may cause temporary discomfort or bruising, and it is unclear if benefits last beyond 12 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of stroke according to the World Health Organization (WHO) (1989) definition. * Stroke diagnosis confirmed by magnetic resonance imaging (MRI). * Patients aged between 18 and 65 years. * Clinically stable condition after stroke. * Patients who have undergone routine Botulinum Toxin Type A (BoNT-A) injection to the gastrocnemius muscle. * Presence of ankle plantar flexor spasticity with a Modified Ashworth Scale (MAS) score of greater than or equal to 1 (MAS ≥ 1). Exclusion Criteria: * Presence of fixed contracture at the ankle joint. * History of prior antispastic surgical procedures. * Changes in antispastic medication dosage or type within the last 6 months. * Active infection or malignancy at the application site. * Presence of a cardiac pacemaker. * Bleeding disorders or advanced vascular disease. * Pregnancy. * Presence of neuromuscular junction disease or motor neuron disease. * Known allergy or hypersensitivity to Botulinum Toxin Type A. * Current use of antibiotics.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-stroke spasticity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Muscle Spasticity stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-stroke spasticity Post-stroke spasticity of the lower limb Spasticity of the plantar flexors Spasticity post stroke Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pamukkale University Faculty of Medicine, Department of Physical Medicine and Rehabilitation

    Denizli, Denizli, 20160, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.